BBIO Research and Charts

BBIO - BridgeBio Pharma Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-11-03 (Delayed quote data 2025-09-12)

Last 51.21	Change ⇓ -1.39 (-2.64%)	Volume 2,087,695
	Open 52.91	High 54.29	Low 51.03

8EMA (Daily) 52.23	40EMA (Daily) 49.11	50EMA (Daily) 48.16	STO (Daily) 78.331	MACD Hist (Daily) -0.204
8EMA (Weekly) 49.635	40EMA (Weekly) 40.01	50EMA (Weekly) 38.38	STO (Weekly) 90.836	MACD Hist (Weekly) 1.127


Company Profile
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.